Document:

stlt_ex104.htm

 EXHIBIT 10.4
  
 ROYALTY AGREEMENT
 (Revised May 1, 2017)
  
 This Royalty Agreement (this "Agreement") is entered into effective as of *Date* (the "Effective Date") by and between Caretta Therapeutics, LLC (the "Company"), and *Print* (the “Subscriber”).
  
 WHEREAS, pursuant to that certain Subscription Agreement (Revised Offering May 1, 2017) dated as of the date hereof for the purchase of certain convertible notes (the “Convertible Notes”), it is contemplated that the Company will pay Subscriber a royalty based on sales of the Company’s prospective Venodol product as set forth herein.
  
 NOW, THEREFORE, the parties agree as follows:
  
 1. Royalty. During Subscriber’s Royalty Term, the Company will pay the Subscriber a royalty calculated in the manner set forth on Schedule A to this Agreement, subject to the Maximum Royalty Amount as set forth on Schedule A (the "Royalty"), and payable as set forth in Section 3.
  
 2. Term. The “Royalty Term” for Subscriber shall mean the period beginning on October 1, 2018, and ending on the date set forth on the table on Schedule B. Notwithstanding the forgoing, the Royalty Term shall terminate upon the payment to Subscriber of the Maximum Royalty Amount.
  
 3. Payment Terms and Report. The Company will pay the foregoing Royalty payments to the Subscriber within thirty (30) days after the end of each calendar quarter. The Company will provide the Subscriber with an quarterly report that details the calculation of Royalty payments.
  
 4. Miscellaneous.
  
 4.1 Notice. Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Agreement must be in writing and will be deemed to have been delivered: (a) upon receipt, when delivered personally, (b) upon receipt, when sent by facsimile (provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending party), or (c) one (1) business day after deposit with an overnight courier service, in each case properly addressed to the party to receive the same. The addresses and facsimile numbers for such communications shall be:
  
 To the Company: 
  
 Caretta Therapeutics, LLC
 11147 Aurora Avenue, Building 3
 Urbandale, Iowa 50322
 Attention: President 
 Telephone: (515) 274-9087
  
  	 
	1
	 
 
	 

  
 If to the Subscriber, to its address and facsimile number set forth at the end of this Agreement, or to such other address and/or facsimile number and/or to the attention of such other person as specified by written notice given to the Company five (5) business days prior to the effectiveness of such change. Written confirmation of receipt (a) given by the recipient of such notice, consent, waiver or other communication, (b) mechanically or electronically generated by the sender’s facsimile machine containing the time, date, recipient facsimile number and an image of the first page of such transmission, or (c) provided by an overnight courier service shall be rebuttable evidence of personal service, receipt by facsimile or receipt from an overnight courier service in accordance with clause (a), (b) or (c) above, respectively.
  
 4.2 Entire Agreement; Amendment; Waiver. This Agreement supersedes all other prior oral or written agreements between the Subscriber, the Company, their affiliates and persons acting on their behalf with respect to the matters discussed herein, and this Agreement and the instruments referenced herein contain the entire understanding of the parties with respect to the matters covered herein and therein and, except as specifically set forth herein or therein, neither the Company nor the Subscriber makes any representation, warranty, covenant or undertaking with respect to such matters. 
  
 4.3 Severability. If any provision of this Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect the validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability of any provision of this Agreement in any other jurisdiction.
  
 4.4 Governing Law; Jurisdiction; Waiver of Jury Trial. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by the internal laws of the State of Iowa, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of Iowa or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of Iowa. Each party hereby irrevocably submits to the non-exclusive jurisdiction of the state and federal courts sitting in Polk County, Iowa for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address for such notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. Each party hereby irrevocably waives any right it may have, and agrees not to request, a jury trial for the adjudication of any dispute hereunder or in connection with or arising out of this Agreement or any transaction contemplated hereby.
  
 4.5 Headings. The headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this Agreement.
  
  	 
	2
	 
 
	 

  
 4.6 Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors and assigns. The Subscriber shall not assign its rights hereunder without the consent of the Company, which consent shall not be unreasonably withheld.
  
 4.7 No Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person.
  
 4.8 Further Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.
  
 4.9 Legal Effect. The Subscriber acknowledges that: (a) it has read this Agreement and the exhibits hereto; and (b) it understands the terms and consequences of this Agreement and is fully aware of its legal and binding effect.
  
 4.10 No Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any party.
  
 4.11 Independent Legal Advice. The parties hereto acknowledge that they have each received independent legal advice with respect to the terms of this Agreement and the transactions contemplated herein or have knowingly and willingly elected not to do so
  
 4.12 Counterparts. This Agreement may be executed in two or more counterparts each of which shall be deemed an original, but all of which shall together constitute one and the same instrument. In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf” signature page were an original thereof.
  
 [Signatures on following page]
  
  	 
	3
	 
 
	 

  
 WHEREAS, the parties have entered into this Royalty Agreement as of the date hereof.
  
  	 CARETTA THERAPEUTICS, LLC
	
	 		 
	By:		
	 Name: 
	John M. Krohn	 
	Title: 	President	 
	 	 	 
	 SUBSCRIBER
	  

	  
	  
	  

	 By:
	  
	  

	 Name:
	 *Print*
	  

	 Address: 
	 *Address*
	  

  
  	 
	4
	 
 
	 

  
 SCHEDULE A
  
 Subscriber: *Print*
  
 Your Royalty Information
  
  	  
Your Investment Amount
	  
Your Royalty Term
	  
Maximum Royalty Amount ($)

	  
*Amount*
	  
October 1, 2018 to *RoyTerm*
	  
*MaxRoyalty*

  
 Subscriber’s Royalty for a particular Royalty Period shall be calculated as follows: (a) the Royalty Pool accrued for the applicable Royalty Period, multiplied by (b) Subscriber’s Royalty Percentage for the applicable Royalty Period.
  
 For purposes of this Agreement, the following definitions shall apply: 
  
 “Affiliated Investment Amount” shall mean the aggregate Investment Amounts of (i) Subscriber and Subscriber’s spouse, (ii) their parents, children, and grandchildren, (iii) entities where the individuals described in subsections (i) and (ii) hold a majority of the outstanding equity interests and voting interests, (iv) revocable trusts formed by the individuals described in subsections (i) and (ii), (v) irrevocable trusts where substantially all of the beneficiaries are individuals described in subsections (i) and (ii), and (vi) retirement accounts for the benefit of individuals described in subsections (i) and (ii). 
  
 “Investment Amount” shall mean the total principal amount of Convertible Notes purchased from the Company. 
  
 “Maximum Royalty Amount” means the Investment Amount multiplied by Max Royalty Multiple set forth on the table below. The Max Royalty Multiple shall be determined by using the Affiliated Investment Amount.
  
 “OTC Roll-On Venodol” shall mean any venom-based analgesic produced by the Company that is available for sale over-the-counter and is distributed in roll-on packaging, regardless of the size of the packaging. 
  
 “OTC Oral Venodol” shall mean any venom-based analgesic produced by the Company that is available for sale over-the-counter and is distributed and packaged for oral ingestion, regardless of the size of the packaging. 
  
 “Prescription Strength Venodol” shall mean any venom-based analgesic produced by the Company that is available for sale only with a prescription from a licensed physician, regardless of the method of use and size of packaging. 
  
 “Royalty Percentage” shall mean, for each Royalty Period, (i) Subscriber’s Investment Amount divided by (ii) the aggregate Investment Amounts of all subscribers that have entered into a Royalty Agreement and whose Royalty Terms include the applicable Royalty Period.
  
  	 
	5
	 
 
	 

  
 “Royalty Period” shall mean a calendar quarter during the Royalty Term. 
  
 “Royalty Pool” shall mean the aggregate of (i) $0.60 for each unit of OTC Roll-On Venodol sold, (ii) $0.60 for each unit of OTC Oral Venodol sold, and (iii) $0.80 for each unit of Prescription Strength Venodol sold during the relevant Royalty Period. The number of units sold during the relevant period shall mean the number of individual products sold by the Company during such period, less any returns received during such period. For purposes of clarity, multi-pack products shall count as multiple units based on the number of included units of product (i.e. a bulk package of 6 OTC Roll-On Venodol bottles shall constitute 6 units).
  
 “Royalty Term” shall mean the period beginning on October 1, 2018 and ending on the date set forth on the following table for the Subscriber’s Affiliated Investment Amount.
  
  	 Affiliated Investment Amount
	 Royalty Term End Date
	 Max Royalty Multiple

	 At least 
	 But less than
		 

	 $25,000
	 $50,000
	 12/31/2023
	 4.00

	 $50,000
	 $100,000
	 12/31/2023
	 5.00

	 $100,000
	 $150,000
	 12/31/2023
	 6.00

	 $150,000
	 $200,000
	 12/31/2023
	 7.00

	 $200,000
	 $250,000
	 9/31/2024
	 8.00

	 $250,000
	 $300,000
	 9/31/2024
	 9.00

	 $300,000
	 $350,000
	 9/31/2024
	 10.00

	 $350,000
	 $400,000
	 9/31/2024
	 11.00

	 $400,000
	 $500,000
	 9/31/2024
	 12.00

	 $500,000
	 $600,000
	 3/31/2025
	 12.25

	 $600,000
	 $700,000
	 3/31/2025
	 12.50

	 $700,000
	 $800,000
	 3/31/2025
	 12.75

	 $800,000
	 $900,000
	 3/31/2025
	 13.00

	 $900,000
	 $1,000,000
	 3/31/2025
	 13.25

	 $1,000,000
	 $1,200,000
	 9/31/2025
	 13.50

	 $1,200,000
	 $1,400,000
	 9/31/2025
	 13.75

	 $1,400,000
	 $1,600,000
	 3/31/2026
	 14.00

	 $1,600,000
	 $1,800,000
	 3/31/2026
	 14.25

	 $1,800,000
	 $2,000,000
	 9/31/2026
	 14.50

	 $2,000,000
	 
	 9/31/2026
	 15.00

  
  
  	 6cosm_ex101.htm

EXHIBIT 10.1
  
  
  	 
	1

	 

	 

  
  
  	 
	2

	 

	 

  
  
  	 
	3

	 

	 

  
  
  	 
	4

	 

	 

  
  
  	 
	5

	 

	 

  
  
  	 
	6

	 

	 

  
  
  	 
	7

	 

	 

  
  
  
  	 8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00277-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00277-of-00352.parquet"}]]